AUG 03, 2015 11:05 PM PDT

Melanoma's Modus Operandi

Why does melanoma, which accounts for 2 percent of skin cancer cases, cause almost all skin cancer deaths? Why have melanoma rates in the US been rising rapidly over the last 30 years? What is melanoma's modus operandi?
Israeli researchers have unlocked puzzling trigger of melanoma.
A new study at Tel Aviv University (TAU), published in Molecular Cell and reported in Drug Discovery & Development, offers insight into the exact trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, showing the exact place in the process where "traveling" cancer turns deadly. Dr. Carmit Levy of the Department of Human Genetics and Biochemistry at TAU's Sackler School of Medicine led the study, which was conducted by a team of researchers from TAU, the Technion Institute of Technology, the Sheba Medical Center, the Institut Gustave Roussy and The Hebrew University of Jerusalem
(http://www.dddmag.com/news/2015/08/researcher-discovers-trigger-deadly-melanoma?et_cid=4710740&et_rid=45505806&location=top).

According to skincancer.org, melanoma is the most dangerous form of skin cancer. Cancerous growths develop when unrepaired DNA damage to skin cells triggers mutations (genetic defects) that cause the skin cells to multiply quickly and form malignant tumors that originate in the pigment-producing melanocytes in the basal layer of the epidermis. Melanomas, which look like moles, sometimes develop from moles. Most are black or brown, but they can also be flesh-colored, pink, red, purple, blue or white. Melanoma, which is caused mostly by intense, occasional UV exposure, especially in those who are genetically predisposed to the disease, kills an estimated 9,940 people in the US annually
(http://www.skincancer.org/skin-cancer-information/melanoma).

Melanoma that is caught in time can be removed and the patient's life saved, but if it invades the bloodstream, turning metastatic, the treatment is aggressive and not always successful. Dr. Levy wanted to know when and how the transformation into aggressive invasion took place. As he explained, "To understand melanoma, I had to obtain a deep understanding about the structure and function of normal skin. Melanoma is a cancer that originates in the epidermis, and in its aggressive form it will invade the dermis, a lower layer, where it eventually invades the bloodstream or lymph vessels, causing metastasis in other organs of the body. But before invading the dermis, melanoma cells surprisingly extend upward, then switch directions to invade. It occurred to me that there had to be a trigger in the microenvironment of the skin that made the melanoma cells 'invasive.' Using the evolutionary logic of the tumor, why spend the energy going up when you can just use your energy to go down and become malignant?"

The researchers collected samples of normal skin cells and melanoma cells from patients at hospitals around Israel, mixed normal and cancerous cells and performed gene analysis expression to study the traveling cancer's behavior. They discovered that, completely independently of any mutation acquisition, the microenvironment alone was the trigger for melanoma metastasis.

According to Dr. Levy "Normal skin cells are not supposed to 'travel.' We found that when melanoma is situated at the top layer, a trigger sends it down to the dermis and then further down to invade blood vessels. If we could stop it at the top layer, block it from invading the bloodstream, we could stop the progression of the cancer."

The researchers discovered that the direct contact of melanoma cells with the remote epidermal layer triggered an invasion by activating "Notch signaling," which activates a set of genes that stimulates changes in melanoma cells, making them invasive. They found that when a molecule expressed on a cell membrane - a spike on the surface of a cell, called a ligand - comes into contact with a melanoma cell, it transforms the cell into an invasive, deadly agent.

Dr. Levy concluded, "Melanoma is a cancer with a very long gestation period. If you can provide a simple kit with precise answers, you can catch it at the beginning stage and hopefully save lives."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 13, 2018
Cancer
JUN 13, 2018
Tailored vaccine boosts survival for some brain cancer patients
In a new multicenter clinical trial, a personalized vaccine improved the survival rates of some people with the deadly brain cancer glioblastoma. Currently...
JUL 09, 2018
Cell & Molecular Biology
JUL 09, 2018
Scientists Found a New Way to Treat Lung Cancer
Small cell lung cancer is an aggressive type that can be fatal; there were few treatments for the disease. That may have changed....
JUL 13, 2018
Genetics & Genomics
JUL 13, 2018
Detecting Leukemia Before it Starts Growing
Researchers have found ways to identify people who may develop an aggressive type of blood cancer while they are still healthy....
JUL 25, 2018
Neuroscience
JUL 25, 2018
Can CT Scans Increase the Risk of Brain Cancer?
Medical imaging has gone from fuzzy X-rays that didn't show much, to real-time functional MRI scans in just a few decades. Being able to see inside the...
JUL 26, 2018
Genetics & Genomics
JUL 26, 2018
When a Cancer Gene Switches Sides
All cells carry a gene named p53, which has a vital role in shielding the body from cancer. But it can betray cells too....
OCT 06, 2018
Genetics & Genomics
OCT 06, 2018
Genetic Mutation Linked to Increased Pancreatic Cancer Risk in Women
In a first, researchers have found a genetic mutation that has a sex-specific effect on pancreatic cancer risk....
Loading Comments...